Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5766219 | 0.87 | MAPK14 (0.43) | MAPK14CA2HTR1AADRA1DADRA1B | |
| SCHEMBL2215555 | 0.87 | MAPK14 (0.43) | MAPK14CA2HTR1AADRA1DADRA1B | |
| SCHEMBL7964858 | 0.85 | ADRA1B (0.49) | MAPK14TDP1TAAR1HTR1AADRA1D | |
| SCHEMBL465772 | 0.85 | CA2 (0.48) | MAPK14TDP1CA2TSHR | |
| SCHEMBL1076666 | 0.85 | CA2 (0.48) | MAPK14TDP1CA2TSHR | |
| SCHEMBL1074704 | 0.85 | CA2 (0.48) | MAPK14TDP1CA2TSHR | |
| SCHEMBL1133834 | 0.82 | ALDH1A1 (0.43) | MAPK14CA2HTR1AADRA1DADRA1B | |
| SCHEMBL1133835 | 0.82 | ALDH1A1 (0.43) | MAPK14CA2HTR1AADRA1DADRA1B | |
| SCHEMBL10760508 | 0.81 | HRH3 (0.41) | MAPK14HTR1AADRA1DADRA1B | |
| SCHEMBL10760342 | 0.81 | MAPK14 (0.40) | MAPK14CA2HTR1AADRA1DADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3173414-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Biosciences Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2188271-B1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA BIOSCIENCES INC (US) | 2017-01-11 | — | — | EP | disclosed |
| US-8252822-B2 | Heterocyclic compounds and uses as anticancer agents | ACEA BIOSCIENCES, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252822-B2 | Heterocyclic compounds and uses as anticancer agents | ACEA BIOSCIENCES, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| WO-2009023402-A2 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA BIOSCIENCES INC. (US) | 2009-02-19 | — | — | WO | disclosed |
| US-20090048271-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Therapeutics, Inc. | 2009-02-19 | — | — | US | disclosed |
| US-20090048271-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Therapeutics, Inc. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048271-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | MKI67, CCNC, HCCS | NFE2L2 1114/4885MAPK14 2242/4885TDP1 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.